John Vandermosten
@vanjohn10
21h
CEO Brendan O'Grady identifies some of the factors that support a higher valuation for Nasus Pharma.
#Biotech #Nasax #SmallCap #Pharma #drugdelivery #NeedleFree $NSRX
youtube.com/shorts/galhYQG…
0
2
2
131
John Vandermosten
@vanjohn10
Nov 6
CFO David McGuire explains the financial options that Spectral AI can offer to providers who want to acquire the DeepView device.
#DeepViewAI #WoundCare #HealthTech #MedTech #LifeSciences #MedicalDevices #DiagnosticTools $MDAI
youtube.com/shorts/rOhij7B…
0
3
3
172
John Vandermosten
@vanjohn10
Nov 5
For all of those who are fans of Issac Asimov and enjoyed the movies I, Robot and the Foundation series as well as embrace the concept of psychohistory, here is a 1987 28-minute interview with the science fiction writer:
freshairarchive.org/segments/dean-…
0
4
4
75
John Vandermosten
@vanjohn10
Nov 5
Nasus Pharma CEO Brendan O'Grady reviews Phase III data of NS002 showing faster absorption of epinephrine compared to Epipen.
#Biotech #Nasax #SmallCap #Pharma #drugdelivery #NeedleFree $NSRX
youtube.com/shorts/yJeV9XZ…
0
0
0
91
John Vandermosten
@vanjohn10
Nov 3
Nasus Pharma CEO Brendan O'Grady shares how many at-risk individuals carry epinephrine.
#Biotech #Nasax #SmallCap #Pharma #drugdelivery #NeedleFree $NSRX
youtube.com/shorts/uBG9RVB…
0
2
3
144
John Vandermosten
@vanjohn10
Nov 3
Nasus Pharma CEO Brendan O'Grady provides highlights for the NS002 trial in anaphylaxis.
#Biotech #Nasax #SmallCap #Pharma #drugdelivery #NeedleFree $NSRX
youtube.com/shorts/m_McfF3…
0
2
3
151
John Vandermosten
@vanjohn10
Nov 3
Protalix to report 3Q results on 10Nov
*Call @ 8 am ET
*Further conference details in PR
$PLX
finance.yahoo.com/healthcare/art…
0
2
4
142
John Vandermosten
@vanjohn10
Oct 31
AEON Biopharma CEO Rob Bancroft discusses the FDA-requested bridging studies for the head to head trials between ABP-450 and Botox.
$AEON #BiotechStocks #Investing #BioTech #Biosimilars #Investors #ABP450 #BotoxBiosimilar #FDAApproval
youtube.com/shorts/v9felrK…
0
2
3
487
John Vandermosten
@vanjohn10
Oct 26
AEON Biopharma CEO Rob Bancroft summarizes ABP-450's analytical studies and other work completed so far to support biosimilarity.
$AEON #BiotechStocks #Investing #BioTech #Biosimilars #Investors #ABP450 #BotoxBiosimilar #FDAApproval
youtube.com/shorts/m05LtL_…
0
1
1
320
John Vandermosten
@vanjohn10
Oct 23
AEON Biopharma CEO Rob Bancroft underscores FDA feedback from Type 2a and 2b meetings.
$AEON #BiotechStocks #Investing #BioTech #Biosimilars #Investors #ABP450 #BotoxBiosimilar #FDAApproval
youtube.com/shorts/WzoC-bi…
0
1
2
322
John Vandermosten
@vanjohn10
Oct 20
CEO Dr. James Bianco identifies some of the conferences where @TuhuraBio may present its ADC-Delta Opioid Receptor data over the next several months.
$HURA #ImmunoOncology #CancerResearch #LifeSciences
youtube.com/shorts/AluiFQ2…
0
1
2
1,062
John Vandermosten
@vanjohn10
Oct 19
Actinium presentation starting now!
John Vandermosten
@vanjohn10
Oct 19
@ActiniumPharma discloses ATNM400 target as HER3
*To present first in human clinical data in mCRPC @ EANM 19Oct, 10:45 ET
*Includes safety, biodistribution, dosimetry & serial PET assessment of tumor uptake and clearance, to inform development & dosing of $ATNM 400
finance.yahoo.com/healthcare/art…
0
1
2
129
John Vandermosten
@vanjohn10
Oct 15
Zacks' Senior Life Sciences Analyst John Vandermosten initiates on AEON Biopharma with a $2.00 price target.
$AEON: Imitation is a Sincere Form of Flattery: Seeking a Botox Biosimilar:
s27.q4cdn.com/906368049/file…
#BiotechStocks #Biosimilars #Biologics #BotulinumToxin #ABP450 #MarketNews
0
2
4
227
John Vandermosten
@vanjohn10
Oct 13
TuHURA CEO Dr. James Bianco looks at next steps for the TBS-2025 program and highlights the NPM1 mutated AML population that will be enrolled in the upcoming Phase Ib trial. $HURA #ImmunoOncology #CancerResearch #LifeSciences
youtube.com/shorts/Az3gDNS…
John Vandermosten
@vanjohn10
Oct 13
US Patent Office issues patent to @TuhuraBio
*Anti-VISTA Antibodies & Uses Thereof
*IP for use as single agent or in combination
*Extends beyond cancer
*Term to 18Feb42
*Complements upcoming Ph1b TBS2025 trial
$HURA
finance.yahoo.com/healthcare/art…
0
2
4
472
John Vandermosten
@vanjohn10
Oct 13
Tuhura Bio CEO Dr. James Bianco looks at next steps for the TBS-2025 program and highlights the NPM1 mutated AML population that will be enrolled in the upcoming Phase Ib trial.
$HURA
#ImmunoOncology #CancerResearch #LifeSciences
youtube.com/shorts/Az3gDNS…
0
2
3
383
John Vandermosten
@vanjohn10
Oct 13
Spectral AI's DeepView showcased @ American College of Emergency Physicians (ACEP) Scientific Assembly
*5-8Oct
*Chicago
*Can engage with emergency dept personnel & introduce DeepView
$MDAI
finance.yahoo.com/healthcare/art…
1
3
7
272
John Vandermosten
@vanjohn10
Oct 13
US Patent Office issues patent to @TuhuraBio
*Anti-VISTA Antibodies & Uses Thereof
*IP for use as single agent or in combination
*Extends beyond cancer
*Term to 18Feb42
*Complements upcoming Ph1b TBS2025 trial
$HURA
finance.yahoo.com/healthcare/art…
0
0
1
440
John Vandermosten
@vanjohn10
Oct 5
CEO Dr. James Bianco provides background to the patent announcement earlier today. He introduces @TuHURA’s ADC program and explains how it can address immunosuppressive MDSCs and block the VISTA checkpoint inhibitor.
$HURA
#ImmunoOncology #CancerResearch #LifeSciences
youtu.be/rT1RLh6db8Y
John Vandermosten
@vanjohn10
Oct 5
@HURA_IR receives patent for Delta Opioid Receptor & Antibody Drug Conjugate technology
*#12,734,168-Delta Opioid Receptor Antagonists Reprogram Immunosuppresive Microenvironment to Boost Immunotherapy
*2043 patent expiry before PTE
$HURA
finance.yahoo.com/healthcare/art…
0
1
2
336
John Vandermosten
@vanjohn10
Oct 2
If @TuhuraBio is successful with its deep-seated tumor trial in Merkel cell carcinoma, it could expand IFx-2.0's addressable market by 30%. Join CEO Dr. James Bianco as he explains.
$HURA
#ImmunoOncology #CancerResearch #LifeSciences

youtube.com/shorts/vl5dwhB…
0
2
4
290
Load more